Executive Order Relaxes Restrictions on Medical Research on Psychedelics
For every drug that finds its name in thousands of criminal complaints every year, there is at least one that is in legal limbo. Consider that nitrous oxide is either a harmless household chemical or the center of a deadly epidemic. Kratom is either a hero or a villain. Lawmakers decided early that heroin is a terrifying force of destruction, while cocaine is a medically approved topical anesthetic which eye surgeons may administer when the situation calls for it; this lack of legal ambiguity enabled authorities to wage wars against these drugs. The Controlled Substances Act decided that heroin is a Bad Drug of the first order; hence, it is a Schedule I controlled substance. All the other drug schedules are for drugs that, under certain circumstances, are legal to administer in a medical setting; consider that cocaine, fentanyl, and oxycodone are Schedule II controlled substances. Meanwhile, there are plenty of drugs that the law considers Schedule I even though plenty of people know from experience that they can be as therapeutic as the drugs that doctors prescribe, especially when it comes to treating conditions like post traumatic stress disorder (PTSD) and opioid addiction. An executive order signed earlier this month authorizes research into several psychedelic substances currently listed as Schedule I drugs. If you are facing criminal charges for possession of psychedelic drugs, contact a Florida drug offenses attorney.
A New Day for Ibogaine in Florida?
In April 2026, President Trump signed an executive order relaxing restrictions on clinical trials on psychedelic substances, to continue investigating their potential as therapies for treatment-resistant clinical depression, opioid use disorder, and PTSD. Veterans’ Affairs hospitals have since announced plans to begin clinical trials on psychedelics. One of the people who attended the executive order signing ceremony was Marcus Luttrell, the author of a memoir about his experience with PTSD after experiencing combat in Afghanistan in the early 2000s and with psychedelic treatments.
Media coverage of the executive order has drawn attention to a psychedelic which may be tested in the upcoming trials, but which, thus far, has not received much media attention. Ibogaine is a compound found in the Tabernanthe iboga shrub, which grows in Central Africa. The drug has been part of traditional medicine in its native range of Gabon, Democratic Republic of Congo, and Republic of Congo for centuries. At low doses, iboga is a stimulant, much like caffeine or nicotine. At higher doses, it produces hallucinogenic visions. Researchers’ biggest worry about iboga is that it can cause heart rhythm dysfunction. Published literature on ibogaine shows that, for weeks after using iboga, patients can experience abnormally long pauses between heartbeats.
Contact FL Drug Defense Group About Drug Cases
A Central Florida criminal defense lawyer can help you if you are facing charges for possession of psychedelic substances that you consider therapeutic but which, according to the law, are Schedule I controlled substances. Contact FL Drug Defense Group in Orlando, Florida to discuss your case.
Source:
npr.org/2026/04/18/nx-s1-5789859/psychedelic-treatments-mental-health
